A novel pharmaceutical combination comprising a cytotoxic antineoplasticagent selected from a group consisting of paclitaxel, docetaxel, doxorubicinor gemcitabine or a pharmaceutically acceptable salt thereof and at least onecyclin dependent kinase (CDK) inhibitor； wherein the said combination exhibitssynergistic effects when used in the treatment of cancer. The invention alsorelates to a method for the treatment of cancer, using a therapeutically effectiveamount of the said combination.
